NAGJI BANSI 4
4 · GoodRx Holdings, Inc. · Filed Sep 16, 2021
Insider Transaction Report
Form 4
Nagji Bansi
President, Healthcare
Transactions
- Sale
Class A Common Stock
2021-09-15$45.03/sh−60,415$2,720,415→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-09-16−29,788→ 309,564 totalExercise: $6.84Exp: 2030-06-15→ Class A Common Stock (29,788 underlying) - Exercise/Conversion
Class A Common Stock
2021-09-15$6.84/sh+60,415$413,239→ 60,415 total - Exercise/Conversion
Class A Common Stock
2021-09-16$6.84/sh+29,788$203,750→ 29,788 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-09-14−89,584→ 481,250 totalExercise: $6.84Exp: 2030-06-15→ Class A Common Stock (89,797 underlying) - Exercise/Conversion
Class A Common Stock
2021-09-14$6.84/sh+89,797$614,211→ 89,797 total - Sale
Class A Common Stock
2021-09-16$45.03/sh−29,788$1,341,488→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-09-14−213→ 399,787 totalExercise: $6.84Exp: 2030-06-15→ Class A Common Stock (213 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2021-09-15−60,415→ 339,372 totalExercise: $6.84Exp: 2030-06-15→ Class A Common Stock (60,415 underlying) - Sale
Class A Common Stock
2021-09-14$45.01/sh−89,797$4,042,023→ 0 total
Footnotes (6)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.11. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.24. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.13. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The option has vested and became exercisable or will vest and become exercisable with respect to the original 700,000 underlying shares of Class A common stock in equal monthly installments over a four year period that commenced on June 10, 2020.
- [F6]The option vested and became exercisable as to 25,000 shares on the closing date of the Issuer's initial public offering of securities, and vested or will vest as to 1/48th of the shares monthly thereafter until fully vested on June 10, 2024.